Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/19/20 → 10/19/20 |
Funding
- Gilead Sciences Incorporated: $3,630.94
A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMARD Therapy
- Patnaik, Asha (PI)
- Liedke, Christopher (CoPI)
- Metzger, Qing (CoPI)
Project: Research